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Abstract
A Body Shape Index (ABSI) and normalized hip circumference (Hip Index, HI) have been
recently shown to be strong risk factors for mortality and for cardiovascular disease in
adults. We conducted an observational cross-sectional study to evaluate the relationship
between ABSI, HI and cardiometabolic risk factors and obesity-related comorbidities in
overweight and obese children and adolescents aged 2–18 years. We performed multivari-
ate linear and logistic regression analyses with BMI, ABSI, and HI age and sex normalized z
scores as predictors to examine the association with cardiometabolic risk markers (systolic
and diastolic blood pressure, fasting glucose and insulin, total cholesterol and its compo-
nents, transaminases, fat mass % detected by bioelectrical impedance analysis) and obe-
sity-related conditions (including hepatic steatosis and metabolic syndrome). We recruited
217 patients (114 males), mean age 11.3 years. Multivariate linear regression showed a sig-
nificant association of ABSI z score with 10 out of 15 risk markers expressed as continuous
variables, while BMI z score showed a significant correlation with 9 and HI only with 1. In
multivariate logistic regression to predict occurrence of obesity-related conditions and
above-threshold values of risk factors, BMI z score was significantly correlated to 7 out of
12, ABSI to 5, and HI to 1. Overall, ABSI is an independent anthropometric index that was
significantly associated with cardiometabolic risk markers in a pediatric population affected
by overweight and obesity.
Introduction
Obesity is one of the most serious international health concerns [1,2]. The increased preva-
lence of obesity in children and adolescents has led to heightened awareness about its impacts
on cardiovascular and metabolic health.
Obesity has been shown to be an independent predictor of some adverse cardiovascular
events, increasing the mortality rate when compared to normal weight subjects [3,4]. In
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children and adolescents obesity is associated with cardiometabolic risk factors, including
hypertension, hyperlipidemia, insulin resistance and type 2 diabetes, which can lead to cardio-
metabolic diseases during adulthood [5,6]. This association implies the need to identify easy,
low-cost, and reliable methods to identify those at most risk.
Since the 1970s, the classification of obesity, for both adults and children, has been based
on weight/height2 (BMI) [2]. BMI identifies patients who are at increased risk of cardiometa-
bolic risk factors [7]. BMI was initially applied to adults, and shown to be highly correlated
with adiposity and cardiovascular risk [8]. In children, BMI z scores are usually used instead of
BMI as standardized measures of weight adjusted for child age and sex. However, BMI is only
a surrogate measure of body fat, because it measures excess weight rather than excess fat, and
the association of childhood BMI z score with cardiometabolic risk is nonlinear [9].
Given these limitations and the heightened awareness of the importance of the sites of fat
deposition for the pathophysiology of cardiometabolic disturbances, researchers have used
other body measures such waist circumference (WC), waist-to-height ratio, and waist-to-hip
ratio to further specify risk, primarily in adult populations. The utility of these anthropometric
indexes in children and adolescents as markers of metabolic comorbidities remains unclear
[10–17].
Recently, new expressions for normalized WC (A Body Shape Index, ABSI) and hip cir-
cumference (Hip Index, HI) have been introduced and have been shown to be risk factors for
mortality and for cardiovascular disease independent of BMI and of each other [17,18]. Con-
sidering that previous studies have shown that abdominal fat is associated with cardiovascular
risk, even in children and adolescents, an index like ABSI, which expresses WC relative to
height and weight, can potentially be a complementary predictor of cardiovascular risk along-
side BMI [19–21]. A study of an adult population recently showed that ABSI was associated
with several components of the metabolic syndrome [22].
To our knowledge, no data are available about the relationship between ABSI and cardio-
vascular risk factors in the pediatric population affected by overweight and obesity.
The main objective of this study is to find the association between the new anthropometric
indexes ABSI and HI and cardiometabolic risk factors and the presence of obesity-related
comorbidities in overweight and obese children and adolescents.
Methods
We performed an observational cross-sectional study. The study participants were recruited
from the obesity outpatient clinic of V. Buzzi Children’s Hospital in Milan (Italy) by retrieving
information from the medical records of the patients from April 1st 2010 to April 30th 2017.
Inclusion criteria include age from 2 to 18 years and diagnosis of overweight or obesity as
detailed below. We excluded children and adolescents affected by genetic/syndromic obesity,
familial hyperlipidemia, use of antihypertensive, antidiabetic, or lipid-lowering medication or
medications such as corticosteroids that affect body composition.
When referred to the clinic, every patient was evaluated by the medical team, including
measurement of systolic (SBP) and diastolic blood pressure (DPB) and pubertal evaluation.
Pubertal stage was assessed according to Tanner [23]. Tanner stages 1 and 2 were combined as
prepubertal/early pubertal, stages 3 and 4 as pubertal, and stage 5 as postpubertal development.
Every patient was also evaluated by a trained dietician, who performed anthropometric mea-
surements (including waist and hip circumference) and bioelectrical impedance analysis (BIA)
as described below.
Every patient was invited to perform blood tests described in the section below within 7
days from the medical visit. Moreover, patients were also invited to be screened within 15 days
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from the medical evaluation by liver ultrasound for detection and quantification of hepatic
steatosis (detailed description below).
All procedures were between 8.00–10.00 AM and were paid for by the National Health Sys-
tem, in accordance with institutional guidelines.
All patients or their parents gave written consent to participate in the study. The study was
approved by the Ethics Committee of ASST-FBF-Sacco (Milan, Italy) and conducted in accor-
dance with the Declaration of Helsinki.
Blood pressure
Peripheral brachial BP was measured by a trained observer using an aneroid sphygmomanom-
eter (TEMA, Model Certus, Italy) 3 times after the patient sat still for at least 5 minutes. Hyper-
tension was defined as BP95th percentile for age, sex, and height as elsewhere reported [24].
Anthropometric measurements
Weight was measured using a medical-certified scale (SECA, Hamburg, Deutschland). Height
was measured using a children’s medical-certified stadiometer (SECA, Hamburg, Deutsch-
land). BMI was calculated as body mass (W, kg) divided by height (H, m) squared. The BMI
values were transformed into BMI z scores using WHO reference values for pediatric BMI
[25].
Overweight was defined by BMI z score between 1 and 2, and obesity as BMI z score 2
(i.e., at least 2 standard deviations above the age- and sex-specific expected value).
Waist and hip circumferences (WC, HC) were measured in centimeters to the nearest 0.1
cm twice using inextensible anthropometric tape positioned parallel to the floor. WC was mea-
sured midway between the lowest border of rib cage and the upper border of iliac crest, at the
end of normal expiration. HC was measured at the widest part of the hip at the level of the
greater trochanter [26].
ABSI was calculated using the following formula ABSI = WC(m)/[BMI2/3 × H (m)1/2] [17].
HI was calculated using the formula HI = HC(cm)  (H / 166 cm)0.310  (W / 73 kg)-0.482
[19]. ABSI and HI values were converted to age and sex specific z scores calculated based on
USA population normals [18].
Blood tests
Blood samples were obtained after a 10-hour overnight fast for measurement of plasma glu-
cose, insulin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total choles-
terol (TC), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol
(LDL), and triglyceride levels (TG) using standard laboratory methods. All samples were ana-
lyzed by the same laboratory. Blood was drawn for glycated haemoglobin (HbA1c) analysis
using a fully automated high-performance liquid chromatography system (Variant II, Bio-Rad
Laboratories, Munich, Germany).
The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated using
the following formula: fasting plasma insulin [in μIU/ml] + fasting plasma glucose [in mmol/l]
 22.5 [27]. The threshold used for insulin resistance was a HOMA-IR value95th percentile
adjusted for gender and Tanner stages according to reference value of HOMA-IR in the Italian
population as described elsewhere [28]. Pancreatic β-cell function (HOMA- β %) was mea-
sured as (20 x fasting insulin in mU/l)/(fasting glucose in mmol/l– 3.5) [27]. Reduced β-cell
function was defined as HOMA- β % value5th percentile, adjusted for gender and Tanner
stage, according to reference values of HOMA- β % in the Italian population as described else-
where [28].
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We used standard cut-off values to define high-risk levels of total cholesterol (hypercholes-
terolemia200 mg/dl), HDL cholesterol (HypoHDL <40 mg/dl, <50 mg/dl for females >16
years), LDL cholesterol (HyperLDL130 mg per deciliter), triglycerides (HyperTG,100
mg/dl for children aged 0–9 years and 130 mg/dl for those aged 10–19 years) [29], and tri-
glycerides/HDL cholesterol ratio (TG-HDL, >2.2) [30,31]. Impaired fasting glucose (IFG) was
defined as fasting plasma glucose level above 100 mg/dl according to the American Diabetes
Association criteria [32].
Liver ultrasonography
Steatosis was identified by ultrasonography based on echogenicity and visualization of vasculature,
parenchyma and diaphragm. Steatosis was scored as follows: absent (score 0), defined as normal
liver echotexture; mild (score 1), slight and diffuse increase in fine parenchymal echoes with nor-
mal visualization of diaphragm and portal vein borders; moderate (score 2), moderate and diffuse
increase in fine echoes with slightly impaired visualization of portal vein borders and diaphragm;
severe (score 3), fine echoes with poor or no visualization of portal vein borders, diaphragm, and
posterior portion of the right lobe [33]. All examinations were performed using an Acuson S2000
ultrasound system (Siemens, Germany) with linear and convex transducers (frequency bandwidth
4-14MHz) by the same operator, who had 10 years of experience in ultrasonography studies.
Bioelectric impedance analysis
Body fat mass expressed in kg (FM kg) and percent body fat mass (FM %) was determined by
a body fat analyzer (Tanita, 780MA, Tanita Corp of America, Inc, Arlington Heights, Ill). This
method for estimating percentage of body fat has a high correlation with dual-energy x-ray
absorptiometry in children [34].
Metabolic syndrome
For metabolic syndrome (MS), we used the International Diabetes Federation (IDF) defini-
tions, which are as follows. For children aged from 10 to 16 years, metabolic syndrome is diag-
nosed with WC above either the 90th percentile or the adult cut-off and the presence of two or
more other features (TG150 mg/dl, HDL-cholesterol < 40 mg/dl, SBP 135 mg/dl, DBP
85 mg/dl, or fasting glucose > 100 mg/dl). For patients age 16 years, MS is diagnosed with
WC 94 cm for men and 80 cm for women, plus any two of the following factors: TG
150 mg/dl, HDL-cholesterol < 40 mg/dl in males and< 50 mg/dl in females, SBP 135
mmHg, DBP85 mmHg, or fasting glucose > 100 mg/dl [35].
Statistical analysis
Multivariate linear regression with age, sex (entered as 0 = male, 1 = female), and z scores of
height, BMI, ABSI, and HI as predictors was used to evaluate which demographic and anthro-
pometric factors were associated with each cardiometabolic risk factor, entered as a continu-
ous predicand variable. Regression coefficients were standardized to enable easier
comparability across predicands, through dividing each predicand by its standard deviation.
Additionally, multivariate logistic regression with the same predictors was used to evaluate
which factors were associated with above-threshold value of each risk factor (including above-
threshold values for the components of metabolic syndrome; presence of metabolic syndrome
for those aged at least 10 years; HOMA-IR95th percentile; HOMA-β %5th percentile; and
presence of hepatic steatosis), entered as a dichotomous predicand variable (0 = absent,
1 = present). All analysis was carried out in the R computing environment.
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Results
From April 1st 2010 to April 30th 2017 we recruited 217 patients (114 males, 103 female, mean
age 11.3 years ± 2.9 standard deviation [SD]) who fulfilled the inclusion criteria. Table 1 gives
the characteristics of the patients.
138 patients (65%) were older than 10 years. 35% were prepubertal and 22% post-pubertal.
188 patients (87%) were obese. Mean ABSI z score was -0.75 ± 1.05 SD. Mean HI z score was
0.06 ± 1.36 SD. All patients were non-smokers.
Table 2 shows means and standard deviations of blood pressure, biochemical variables and
fat mass in our patients.
Table 3 shows the cardiometabolic comorbidities of our patients.
As defined based on age, height and gender specific percentiles, 16/205 (7.8%) patients had
systolic hypertension and 3.4% diastolic hypertension All the hypertensive patients were aged
10–17 years old. Detected alterations in lipid profile included hypoHDL cholesterol values
(22%), hyperTG (20%), hypercholesterolemia (10.3%), and hyperLDL cholesterol (10%).
TG/HDL was2.2 in 34% of patients.
IFG was found in 8.2% of our patients (17/207). HOMA-IR value95th was found in 25%
of our population (46/184), with a higher frequency in males compared to females (33.6% ver-
sus 15.1%). Reduced β cell function was found in 5.4% of patients (10/184), with an incidence
of 7.1% in males compared to 3.4% in females.
Table 1. Patient characteristics.
Patients’ characteristics N (%)
Gender
Female 103 (47)
Male 114 (53)
Ethnicity
Caucasian 179 (82)
Hispanic 15 (7)
Asian 15 (7)
African 8 (4)
Age (Years) (Mean, SD) 11.3 (2.9)
Age 3–5 years 10 (5)
Age 6–9 years 63 (29)
Age 10–17 years 138 (65)
Tanner stage
Prepubertal/early pubertal 7(35)
Pubertal 94 (44)
Post pubertal 47 (22)
Weight (kg) (mean, SD) 63 (20)
Height (cm) (mean, SD) 150 (16)
Height z score (mean, SD) 0.70 (1.11)
BMI (mean, SD) 27.3 (4.4)
BMI z score (mean, SD) 2.81 (0.91)
Overweight 29 (13)
Obese 188 (87)
ABSI z score (mean, SD) -0.75 (1.05)
HI z score (mean, SD) 0.06 (1.36)
ABSI: A Body Shape Index; BMI: body mass index, HC: hip circumference, HI: Hip Index; N: number; SD:
standard deviation
https://doi.org/10.1371/journal.pone.0190426.t001
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Table 2. Blood pressure, biochemical variables and fat mass.
Variable Total Males Females
N Mean ± SD N Mean ± SD N Mean ± SD
SBP (mmHg) 205 107 (14) 111 107 (13) 94 107 (15)
DBP (mmHg) 205 65 (10) 111 65 (9) 94 64 (10)
Glucose (mg/dl) 207 87 (10) 108 87 (10) 99 87 (11)
Insulin (μU/ml) 189 12.3 (7.5) 101 12.0 (8.1) 88 12.6 (6.8)
Hba1c (mmol/mol) 189 35.9 (4.4) 98 35.9 (4.0) 91 35.9 (4.8)
HOMA IR 184 2.66 (1.74) 98 2.56 (1.89) 86 2.78 (1.55)
HOMA β% 184 199 (138) 98 189 (150) 86 211 (124)
TC (mg/dl) 213 162 (29) 113 162 (29) 100 162 (28)
HDL (mg/dl) 211 48 (10) 112 46 (10) 99 49 (10)
LDL(mg/dl) 211 96 (25) 112 97 (26) 99 96 (24)
TG (mg/dl) 216 89 (51) 114 93 (59) 102 85 (40)
TG/HDL 211 2.04 (1.50) 112 2.22 (1.78) 99 1.82 (1.06)
AST (U/L) 197 26.2 (8.8) 104 28.4 (9.3) 93 23.8 (7.5)
ALT (U/L) 195 26.6 (19.0) 103 30.6 (22.9) 92 22.1 (12.1)
FM (kg) 129 23.7 (9.6) 73 22.0 (7.3) 56 25.9 (11.7)
FM (%) 129 34.7 (6.0) 73 33.6 (5.9) 56 36.2 (5.8)
ALT: alanine aminotransferase, AST: aspartate aminotransferase, DPB: diastolic blood pressure, FM: fat mass, HbA1c: glycated hemoglobin; HDL: high-
density lipoprotein cholesterol, HOMA–IR: Homeostatic Model Of Assessment–IR, HOMA β%: Homeostatic Model Of Assessment β%, LDL: low-density
lipoprotein cholesterol, N: number of subjects with available data, SBP: systolic blood pressure, SD: standard deviation, TC: total cholesterol, TG:
triglycerides; U: Unit.
https://doi.org/10.1371/journal.pone.0190426.t002
Table 3. Prevalence of cardiometabolic risk factors and obesity-related comorbidities.
Cardiometabolic risk factors
N‡/total
population
Female
N‡/total
F
Males
N‡/total
M
Age
3–5 y
(N‡/tot)
Age
6–9 y
(N‡/tot)
Age
10–17 y
(N‡/tot)
Pre
pubertal
(N‡/tot)
Pubertal
(N‡/tot)
Post
pubertal
(N‡/tot)
Systolic
hypertension*
16/205 7/94 9/111 0/10 0/61 16/134 0/72 10/88 6/44
Diastolic
hypertension*
7/205 3/94 4/111 0/10 0/61 7/134 0/72 5/88 2/44
HyperTC 22/213 10/100 12/113 0/10 5/63 17/140 6/75 10/91 6/46
Hyper LDL 25/211 8/99 17/112 0/10 8/62 17/139 10/74 11/91 4/45
HypoHDL 46/209 19/99 27/112 5/10 13/62 28/139 20/74 18/91 8/45
HyperTG 44/216 17/102 27/114 2/10 19/63 23/143 21/75 17/93 6/47
TG/HDL2.2 72/211 28/99 44/112 3/10 23/62 46/139 32/74 29/91 11/45
IFG 17/207 7/99 10/108 0/9 5/59 12/139 4/71 9/91 4/44
HOMA-IR95th centile † 46/184 13/86 33/98 2/7 11/52 33/125 17/61 22/85 7/37
HOMA β cell5th centile† 10/184 3/86 7/98 0/7 4/52 6/125 5/61 5/85 0/37
* for gender, age and height
† for gender, and Tanner stages.
N‡: number of subjects affected.
N‡/tot: the number of subjects affected and the total number assessed in each subgroup.
DBP 95th percentile; F: female; Hyper LDL130 mg/dl; HyperTC200 mg/dl; HyperTG150 mg per deciliter HypoHDL <40 mg/dl (<50 for females
aged 16 y); IFG: impaired fasting glucose; M: male; SBP 95th percentile; y: years.
https://doi.org/10.1371/journal.pone.0190426.t003
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Relatively few patients met the MS IDF definition (10/132 out of those 10 years of age),
even though most (68/132) had WC above 90th percentile.
The prevalence of hepatic steatosis was 30% (50/162 patients); of those patients 6% had
severe steatosis.
Multivariate linear regression (Table 4) showed that ABSI z-score correlated with 10 out of
15 risk markers expressed as continuous variables, while BMI z score showed a significant cor-
relation with 9 and HI only with 1.
ABSI z score showed a significant positive correlation with serum insulin (standardized
regression coefficient 0.22), HOMA–IR (0.18), HOMA β% (0.17), TC (0.15), LDL (0.20), TG
(0.15), ALT (0.19), FM% (0.17), TG/HDL (0.21). BMI z score positively correlated with SBP
(standardized regression coefficient 0.56), DBP (0.37), insulin (0.28), HOMA β% (0.29), TG
Table 4. Standardized coefficients (with 95% confidence intervals) from multiple linear regression of risk factors on sex, age, and anthropometric
indices.
N Sex (M = 0,
F = 1)
Age (y) Height z
score
BMI z score ABSi z score HI z score Regression
adjusted R2
SBP 187 0.19 (-0.06,
0.43)
0.28 (0.23,
0.33)
0.15 (0.04,
0.26)
0.56 (0.40,
0.71)
0.07 (-0.04,
0.19)
-0.05 (-0.13,
0.03)
0.47
DBP 187 0.04 (-0.24,
0.33)
0.21 (0.16,
0.27)
0.09 (-0.03,
0.22)
0.37 (0.19,
0.55)
-0.01 (-0.14,
0.12)
0.01 (-0.09,
0.10)
0.27
Glucose 189 0.08 (-0.25,
0.41)
-0.01 (-0.08,
0.05)
-0.05 (-0.20,
0.10)
-0.02 (-0.23,
0.20)
0.12 (-0.03,
0.27)
-0.04 (-0.15,
0.07)
-0.01
Insulin 174 0.44 (0.15,
0.74)
0.15 (0.09,
0.21)
0.21 (0.08,
0.35)
0.28 (0.08,
0.47)
0.22 (0.09,
0.36)
0.01 (-0.09,
0.10)
0.14
Hba1c 172 -0.06 (-0.39,
0.26)
0.10 (0.04,
0.16)
-0.01 (-0.16,
0.14)
0.17 (-0.04,
0.38)
-0.02 (-0.18,
0.13)
-0.10 (-0.22,
0.02)
0.07
HOMA IR 199 0.36 (0.06,
0.67)
0.11 (0.05,
0.17)
0.19 (0.05,
0.32)
0.15 (-0.04,
0.35)
0.18 (0.03,
0.32)
-0.01 (-0.11,
0.10)
0.07
HOMA β 169 0.43 (0.12,
0.73)
0.16 (0.10,
0.22)
0.25 (0.11,
0.40)
0.29 (0.09,
0.49)
0.17 (0.03,
0.31)
0.01 (-0.09,
0.12)
0.14
TC 195 0.07 (-0.24,
0.39)
0.01 (-0.04,
0.08)
-0.04 (-0.18,
0.10)
0.05 (-0.15,
0.25)
0.15 (0.01,
0.30)
0.02 (-0.09,
0.12)
-0.01
HDL 193 0.03 (-0.28,
0.33)
-0.04 (-0.10,
0.02)
-0.04 (-0.17,
0.10)
-0.34 (-0.53,
-0.14)
-0.25 (-0.39,
-0.11)
0.02 (-0.08,
0.13)
0.10
LDL 193 0.07 (-0.24,
0.38)
0.02 (-0.03,
0.08)
-0.02 (-0.15,
0.12)
0.09 (-0.10,
0.29)
0.20 (0.06,
0.35)
0.03 (-0.07,
0.14)
0.02
TG 198 0.04 (-0.27,
0.35)
0.04 (-0.02,
0.10)
-0.03 (-0.17,
0.10)
0.24 (0.04,
0.44)
0.15 (0.01,
0.30)
-0.07 (-0.18,
0.03)
0.03
TG/HDL 193 -0.02 (-0.32,
0.29)
0.03 (-0.03,
0.09)
-0.05 (-0.18,
0.09)
0.29 (0.09,
0.49)
0.21 (0.06,
0.35)
-0.05 (-0.15,
0.05)
0.06
AST 181 -0.46 (-0.76,
-0.16)
-0.06 (-0.12,
0.00)
0.05 (-0.09,
0.18)
0.16 (-0.04,
0.35)
0.13 (-0.02,
0.29)
-0.07 (-0.17,
0.04)
0.15
ALT 180 -0.29 (-0.58,
0.01)
0.07 (0.01,
0.13)
0.17 (0.04,
0.30)
0.35 (0.16,
0.54)
0.19 (0.05,
0.33)
0.01 (-0.09,
0.11)
0.17
FM % 114 0.77 (0.45,
1.08)
0.07 (0.00,
0.14)
-0.09 (-0.23,
0.05)
0.98 (0.77,
1.18)
0.17 (0.00,
0.33)
0.15 (0.01,
0.29)
0.47
Number of significant
associations
5/15 8/15 5/15 9/15 10/15 1/15
Coefficients represent standard deviations of risk factor (see Table 1 for the standard deviation values) per year of age, female vs. male sex, or unit change
in z score. Values in bold represent significant associations.
ABSI: A Body Shape Index; ALT: alanine aminotransferase, AST: aspartate aminotransferase, BMI: Body Mass Index, DPB: diastolic blood pressure, F:
females, FM: fat mass, HbA1c: glycated gemoglobin, HDL: high-density lipoprotein cholesterol, HI: Hip Index, HOMA–IR: Homeostatic Model Of
Assessment–IR, HOMA β%: Homeostatic Model Of Assessment β%, LDL: low-density lipoprotein cholesterol, M: males, N: number of subjects, SBP:
systolic blood pressure, TC: total cholesterol, TG: triglycerides, y: years
https://doi.org/10.1371/journal.pone.0190426.t004
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(0.24), ALT (0.35), FM % (0.98), TG/HDL (0.29). Both BMI z score and ABSI z score showed a
significant negative correlation with HDL cholesterol (coefficient -0.34 and -0.25 respectively).
HI was associated only with FM% (coefficient 0.15) (Table 4).
Table 5 shows odds ratios from multiple logistic regression of dichotomous risk factors on
sex, age, and anthropometric indices.
BMI z score was positively correlated to probability of systolic hypertension (odds ratio
[OR] 3.5; Table 5), diastolic hypertension (2.4), hypoHDL (1.8), MS (4.7) and presence of
hepatic steatosis (3.6) TG/HDL 2.2 (1.7). ABSI was correlated with hypoHDL (OR 1.5),
hyperTG (1.6), HOMA-IR value95% (1.7), TG/HDL2.2 (1.4) and hepatic steatosis (1.7).
Discussion
This is the first study that investigates the potential relationship in overweight and obese chil-
dren and adolescents between the new anthropometric indexes ABSI and HI, along with BMI,
and cardiovascular and obesity-related risk factors.
Table 5. Odds ratios (with 95% confidence intervals) from multiple logistic regression of dichotomous risk factors on sex, age, and anthropomet-
ric indices.
N‡/tot Sex
(M = 0,
F = 1)
Age (y) Height z score BMI z score ABSI
z score
HI
z score
Regression pseudo R2
High SBP* 16/187 0.8
(0.2, 3.2)
1.7
(1.3, 2.3)
1.0
(0.5, 1.8)
3.5
(1.6, 8.7)
0.7
(0.4, 1.4)
0.7
(0.5, 1.0)
0.32
High DBP* 7/187 0.6
(0.1, 3.9)
1.4
(1.0, 2.0)
0.7
(0.3, 1.6)
2.4
(1.0, 6.2)
0.9
(0.3, 2.1)
0.8
(0.5, 1.5)
0.22
HyperTC 20/195 1.3
(0.5, 3.9)
1.2
(1.0, 1.5)
1.2
(0.8, 1.9)
1.5
(0.8, 2.6)
1.3
(0.8, 2.2)
1.0
(0.7, 1.5)
0.17
HyperTG 38/198 1.4
(0.6, 3.2)
1.1
(0.9, 1.2)
1.2
(0.8, 1.7)
1.6
(1.0, 2.6)
1.6
(1.1, 2.4)
0.8
(0.6, 1.1)
0.25
HyperLDL 22/193 0.6
(0.2, 1.5)
1.1
(0.9, 1.3)
1.1
(0.7, 1.7)
1.4
(0.7, 2.4)
1.0
(0.6, 1.5)
1.1
(0.8, 1.5)
0.19
HypoHDL 41/193 1.2
(0.5, 2.6)
1.0
(0.9, 1.2)
0.8
(0.6, 1.2)
1.8
(1.1, 3.0)
1.5
(1.0, 2.2)
1.1
(0.9, 1.5)
0.24
TG/HDL2.2 66/193 1.0
(0.5, 2.0)
1.1
(1.0, 1.3)
1.2
(0.9, 1.6)
1.7
(1.1, 2.8)
1.4
(1.0, 2.0)
0.8
(0.7, 1.1)
0.23
IFG 16/189 0.8
(0.2, 2.4)
1.0
(0.8, 1.3)
0.9
(0.5, 1.4)
1.1
(0.5, 2.2)
1.0
(0.6, 1.7)
0.7
(0.5, 1.0)
0.14
MS † 12/126 1.4
(0.3, 6.0)
1.1
(0.7, 1.7)
1.1
(0.6, 2.0)
4.7
(1.7, 18.7)
1.3
(0.6, 2.6)
0.8
(0.5, 1.4)
0.20
HOMA-IR95th centile ‡ 41/169 0.6
(0.2, 1.3)
1.3
(1.1, 1.5)
1.8
(1.2, 2.7)
1.7
(1.0, 3.0)
1.7
(1.1, 2.5)
1.0
(0.7, 1.3)
0.34
HOMA- β 5th centile ‡ 10/169 0.1
(0.0, 0.6)
0.5
(0.3, 0.8)
0.7
(0.3, 1.4)
0.2
(0.0, 0.6)
0.5
(0.2, 1.1)
1.1
(0.7, 1.8)
0.24
Hepatic steatosis 46/147 0.7
(0.3, 1.8)
1.3
(1.1, 1.5)
1.1
(0.7, 1.6)
3.6
(1.9, 7.5)
1.7
(1.1, 2.7)
0.9
(0.7, 1.3)
0.35
Number of significant associations 1/12 4/12 1/12 7/12 5/12 2/12
* for gender, age and height
† Patients age 10 years only
‡ for gender, and Tanner stages.
N‡/tot: the number of subjects affected out of the subgroup of patients with available parameters.
The odds ratios are per year of age, female vs. male sex, or unit change in z score. Values in bold represent significant associations.
DBP 95th percentile; Hyper LDL130 mg/dl; Hyper TC200 mg/dl; HyperTG150 mg/dl; HypoHDL <40 mg/dl (<50 for females aged 16 y); IFG:
impaired fasting glucose; SBP 95th percentile; TG-HDL ratio > 2.2
https://doi.org/10.1371/journal.pone.0190426.t005
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In multiple linear regression of cardiometabolic variables on anthropometric indexes, ABSI
z score showed significant correlation with 10/15 cardiometabolic risk markers, expressed as
continuous variables: positive correlation with fasting insulin, HOMA-IR and HOMA β%, TC,
LDL, TG, ALT, TG/HDL as well as with FM%, and a negative correlation with HDL. BMI z
score showed significant correlation with 9/15 markers: positive correlations with SBP, DBP,
insulinemia, HOMA β%, TG, ALT, TG/HDL, FM%, and a negative correlation with HDL.
Thus, ABSI z score was found to correlate with glucose metabolism indexes and the whole
lipid profile, including TG/HDL, which was recently found as a biomarker of atherogenic dys-
lipidemia and altered cardiometabolic risk. BMI was positively associated with blood pressure
and FM% (0.98 –C.I. 95% 0.77–1.18). Our results are intriguing considering that ABSI, which
expresses WC relative to height and weight, has been proposed as a new and more effective
method to quantify the specific risk associated with abdominal obesity (AO). The role of AO
has been extensively studied in the last years in adult population, but in children is far from
being completely elucidated [36]. Visceral fat, due to its location and metabolic characteristics,
contributes to distorted metabolism to a much greater extent than subcutaneous fat [37]. Find-
ings from a recent systematic review showed that central body fat deposition in children and
adolescents seems to increase the probability of having cardio-metabolic risk factors [38]. Our
results support the association between AO and worse lipid profile and glucose metabolism
indexes, suggesting that AO promotes a cluster of atherogenic and diabetes-related risk factors.
On the other hand, when considering the percentage of FM, BMI showed a strong association
compared to ABSI and HI (regression coefficient 0.98 vs 0.17 vs 0.15, respectively), suggesting
that other sites than the abdominal, including subcutaneous fat around the hip, could be over-
represented in children and adolescents with obesity. Recently, ectopic fat, such as hepatic and
pancreatic fat, was more fully investigated in pediatric populations, and some authors pro-
posed that its accumulation could contribute to the risk of metabolic syndrome and impaired
insulin response [39,40]. In support of this hypothesis we found that BMI showed a stronger
correlation than ABSI (regression coefficient 0.35 vs 0.19) with ALT level, the most widely
used first line marker of nonalcoholic fatty liver disease [41]. Imaging techniques would be
useful in assessing this hypothesis.
We also analyzed cardiometabolic risk factors as dichotomous variables, using the most
widely accepted thresholds to identify elevated cardiovascular risk. We found that ABSI was
significantly correlated with 5/12 obesity-related cardiovascular risk factors: hypoHDL,
HOMA-IR value95th, hyperTG, elevated TG/HDL and the presence of hepatic steatosis. HI
was significantly correlated only with impaired fasting glucose.
Using multivariate logistic regression to model the likelihood of above-threshold values,
BMI was associated with a greater number of obesity-related cardiovascular risk factors (7/12)
compared to ABSI, including systolic and diastolic hypertension, hypoHDL, elevated TG/
HDL, metabolic syndrome, reduced β cell function and hepatic steatosis. The last two findings
support the role of BMI in representing also ectopic fat accumulation (such as pancreatic and
hepatic fat) in children, as discussed previously.
Our study suggests that in children and adolescents affected by overweight and obesity,
ABSI seemed a more suitable cardiovascular risk predictor when considering metabolic mark-
ers, while on the other hand BMI was better correlated with the presence of obesity-related
threshold-based risk factors.
We can speculate about the stronger association between ABSI and many cardiometabolic
markers compared to the weaker association of ABSI with obesity-related conditions expressed
in terms of thresholds. It is well known that cut points are not precise for delineating those at
excess risk and limit the accurate identification of the at-risk child. Considering risk factors as
continuous variables, we found that ABSI correlated with many cardiometabolic markers,
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further suggesting that the current cut-offs are incomplete indicators of increased risk. It is
likely that in the future these thresholds will be revised or made more nuanced based on accu-
mulating population-based findings.
Our study has some limitations. The population we analyzed was relatively small in size,
constraining the power of multivariate regression to identify and rank anthropometric predic-
tors, and limited to participants in a pediatric obesity clinic. For many of the risk factors and
for the presence of MS, only a small percentage of the cohort was above the threshold, suggest-
ing the need for a much larger sample to better quantify associations of risk factors and MS
with anthropometrics in children and adolescents. With a larger sample size, it will also be pos-
sible to investigate nonlinear associations of BMI and HI with risk factors, as previously found
for mortality risk [18]. Additionally, only a small percentage of patients were of non-Caucasian
ethnicity. Large and long-term population studies are therefore needed to better establish the
value of these new indexes in pediatric populations.
Conclusions
The recently proposed ABSI was found to complement BMI as a marker of cardiometabolic
and obesity-related risk factors in overweight and obese children attending an outpatient
clinic. Overall, ABSI was of comparable power to BMI as a predictor of risk factors. ABSI
seemed a more suitable cardiovascular risk predictor when considering metabolic markers,
while on the other hand BMI was better correlated with the presence of obesity-related thresh-
old-based risk factors.
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